Business OpportunityUpdated on 17 March 2026
Personalized cancer vaccine in TNBC
Direttore scientifico at Neomatrix SRL
roma, Italy
About
Neomatrix has validated in preclinical animal models a personalized cancer vaccine for Triple Negative Breast Cancer (TNBC) in collaboration with Targo TX in UK. We plan to submit a clinical trial authorization for which we are looking for collaboration to transfer the RNA-LNP production process to describe the CMC and submit the CTA to EMA
Stage
- TRL 6
Topic
- Bioinformatics
- Genomics
- Neoplasms/cancer/oncology
Sector
- ATMPs
- Oncology
Type
- Research collaboration
- Co-development
- Clinical validation
- Regulatory expert
Organisation
Similar opportunities
Business Opportunity
- AI
- TRL 7
- Oncology
- Diagnostics
- Bioinformatics
- Clinical validation
- Consortium partners
- Neoplasms/cancer/oncology
Marc Vargas
Project Manager in Digital Pathology at Palex
Barcelona, Spain
Business Opportunity
Preclinical Platform for ATMP Evaluation with Patient-Derived Microtumours (PDMs)
- AI
- TRL 6
- ATMPs
- Genomics
- Oncology
- Proteomics
- Health data
- Diagnostics
- Bioinformatics
- Co-development
- Regulatory expert
- Consortium partners
- Research collaboration
- Neoplasms/cancer/oncology
Martin Kriebel
Senior Principal Scientist Next Generation Cellular and Organotypic Assays at NMI Natural and Medical Sciences Institute
Reutlingen, Germany
Business Opportunity
Implement Cancer Genome Interpretater (CGI) in oncology - Looking for clinical sites
- AI
- TRL 7
- Genomics
- Oncology
- Licensing
- Diagnostics
- Bioinformatics
- Regulatory expert
- Clinical validation
- Consortium partners
Olivia Tort
CGI-Clinics project manager at IRB Barcelona
Barcelona, Spain